Postmenopausal Iron Overload Exacerbated Bone Loss by Promoting the Degradation of Type I Collagen
Table 1
Baseline characteristics in Normal, Bone Loss, and Osteoporosis groups series.
Patients
Normal
Bone Loss
Osteoporosis
(28)
(71)
(18)
Ages (yrs)
66.89 ± 11.54
70.61 ± 9.11▲
77.61 ± 10.43
Femoral neck (-Score)
−0.39 ± 0.88
−1.75 ± 0.75
−3.22 ± 0.53
L1–L4 (-Score)
−0.36 ± 0.62
−1.87 ± 0.88
−3.53 ± 0.53
25-OH (mmol/L)
43.59 ± 9.13
43.05 ± 19.36
44.07 ± 22.71
Height (cm)
158.33 ± 5.89
158.55 ± 3.71
154.94 ± 4.48
Weight (kg)
57.89 ± 9.43
59.03 ± 8.96
49.94 ± 9.61
BMI
23.12 ± 3.76
23.38 ± 3.10
20.74 ± 3.61
Ca (mmol/L)
2.25 ± 0.10
2.24 ± 0.14
2.18 ± 0.13
P (mmol/L)
1.06 ± 0.18
1.10 ± 0.19
1.11 ± 0.24
Years of menopause (yrs)
15.89 ± 9.71
19.99 ± 8.63
27.33 ± 11.79
Hemoglobin (g/L)
113.33 ± 16.05
117.66 ± 19.73
105.11 ± 16.02
CRP (mg/L)
8.47 ± 4.37
8.77 ± 4.56▲
9.74 ± 4.98
WBC (109/L)
6.92 ± 2.00
6.80 ± 2.16
6.83 ± 1.51
N (%)
70.56 ± 10.55
69.66 ± 9.84
71.35 ± 9.29
Total CO2 (mmol/L)
26.66 ± 2.21
25.27 ± 2.20
25.22 ± 6.01
Creatinine (U/L)
53.22 ± 8.47
56.45 ± 20.05
58.06 ± 13.14
Uric acid (μmol/L)
213.56 ± 36.37
268.35 ± 74.62
232.33 ± 79.38
Triglycerides (mmol/L)
0.87 ± 0.33
1.25 ± 0.71
1.33 ± 1.52
Total cholesterol (mmol/L)
4.54 ± 1.14
4.91 ± 1.02
4.67 ± 0.97
AST (U/L)
21.00 ± 5.59
25.34 ± 19.13
24.56 ± 11.42
ALT (U/L)
17.56 ± 7.76
20.03 ± 20.88
19.28 ± 12.82
Glucose (mmol/L)
6.28 ± 0.89
5.71 ± 1.06
5.83 ± 0.98
Note. ▲ means significant difference compared with the Normal group, . means significant difference compared with the Normal group, . means significant difference compared with the Normal group, .
